CA2513660C — Hydroxyl compounds and compositions for cholesterol management and related uses
Assigned to Esperion Therapeutics Inc · Expires 2012-05-08 · 14y expired
What this patent protects
The present invention relates to a compound of formula I: (see formula I) wherein R1, R2, R11, R12, Y1, Y2, X, n and m are as defined in the claims, compositions comprising the compound, and methods useful for treating and preventing a variety of diseases and conditions. In cert…
USPTO Abstract
The present invention relates to a compound of formula I: (see formula I) wherein R1, R2, R11, R12, Y1, Y2, X, n and m are as defined in the claims, compositions comprising the compound, and methods useful for treating and preventing a variety of diseases and conditions. In certain embodiments, the compound, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
Drugs covered by this patent
- Nexletol (BEMPEDOIC ACID) · Esperion Theraps Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.